Becton Dickinson and Company (BDX) · Insider trading
What Becton Dickinson's directors, officers and largest holders bought and sold themselves, from the Form 4 each of them files with the SEC within two business days of a trade. Open-market purchases and sales first: those are the trades somebody chose to make at the market price.
Bought, 12 months
$0
0 insiders, 0 trades
Sold, 12 months
$2.78M
5 insiders, 77% under a plan
Net, 12 months
−$2.78M
bought less sold
Latest filing
2026-09-29
filings read to 2026-10-19
Who traded, two years
| Insider | Bought | Sold | Trades | Last trade | Holds after |
|---|---|---|---|---|---|
| Garrison Michael DavidEVP & Pres Med.Essntl&BioPharm | – | $1.87M | 10 | 2026-06-24 | 13,172 |
| Goette RolandEVP and President, EMEA | – | $1.57M | 3 | 2026-08-11 | 14,856 |
| Polen Thomas E JrDirector, Chairman, CEO and President | – | $1.17M | 2 | 2026-08-13 | 110,163 |
| Hayes GregoryDirector | $1.01M | – | 1 | 2025-08-11 | 6,046 |
| Shan DavidEVP and Chief ISC Officer | – | $649,983 | 3 | 2025-06-02 | 4,575 |
| Neal Shana CarolEVP and Chief People Officer | – | $594,550 | 3 | 2025-01-21 | 15,414 |
| Byrd RichardEVP & President Interventional | – | $541,895 | 2 | 2025-03-18 | 6,952 |
| Scott Bertram LDirector | – | $371,938 | 3 | 2026-02-18 | 36,763 |
| Henderson Jeffrey WilliamDirector | $350,430 | – | 1 | 2025-02-10 | 8,015 |
| Fraser ClaireDirector | – | $337,892 | 2 | 2025-09-10 | 22,226 |
| Feld MichaelEVP, Chief Revenue Officer | – | $192,606 | 14 | 2026-09-28 | 19,644 |
Open-market purchases and sales
Newest first. “Plan” marks a trade made under a 10b5-1 plan set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Holds after | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-28 | Feld MichaelEVP, Chief Revenue Officer | Saleplan | 76 | 183.70 | $13,961 | 19,644 | Form 4 |
| 2026-08-26 | Feld MichaelEVP, Chief Revenue Officer | Saleplan | 165 | 188.49 | $31,101 | 19,720 | Form 4 |
| 2026-08-13 | Polen Thomas E JrDirector, Chairman, CEO and President | Saleplan | 4,152 | 185.00 | $768,120 | 110,163 | Form 4 |
| 2026-08-11 | Goette RolandEVP and President, EMEA | Sale | 2,438 | 180.84 | $440,888 | 14,856 | Form 4 |
| 2026-07-27 | Feld MichaelEVP, Chief Revenue Officer | Saleplan | 75 | 157.13 | $11,785 | 20,934 | Form 4 |
| 2026-06-26 | Feld MichaelEVP, Chief Revenue Officer | Saleplan | 75 | 152.80 | $11,460 | 21,009 | Form 4 |
| 2026-06-24 | Garrison Michael DavidEVP & Pres Med.Essntl&BioPharm | Saleplan | 1,100 | 145.66 | $160,226 | 13,172 | Form 4 |
| 2026-06-10 | Garrison Michael DavidEVP & Pres Med.Essntl&BioPharm | Saleplan | 1,100 | 151.48 | $166,628 | 14,272 | Form 4 |
| 2026-06-01 | Polen Thomas E JrDirector, Chairman, CEO and President | Saleplan | 2,764 | 146.35 | $404,511 | 110,163 | Form 4 |
| 2026-05-26 | Feld MichaelEVP, Chief Revenue Officer | Saleplan | 75 | 147.35 | $11,051 | 21,084 | Form 4 |
| 2026-04-27 | Feld MichaelEVP, Chief Revenue Officer | Saleplan | 74 | 151.94 | $11,244 | 21,159 | Form 4 |
| 2026-03-26 | Feld MichaelEVP, Chief Revenue Officer | Saleplan | 75 | 156.83 | $11,762 | 21,233 | Form 4 |
| 2026-02-26 | Feld MichaelEVP, Chief Revenue Officer | Saleplan | 75 | 181.84 | $13,638 | 21,308 | Form 4 |
| 2026-02-18 | Scott Bertram LDirector | Sale | 953 | 182.61 | $174,027 | 36,763 | Form 4 |
| 2026-01-26 | Feld MichaelEVP, CRO & Pres. Life Sciences | Saleplan | 75 | 202.73 | $15,205 | 16,431 | Form 4 |
| 2026-01-15 | Garrison Michael DavidEVP & Pres Med.Essntl&BioPharm | Saleplan | 600 | 209.00 | $125,400 | 13,105 | Form 4 |
| 2026-01-15 | Garrison Michael DavidEVP & Pres Med.Essntl&BioPharm | Saleplan | 1,010 | 206.54 | $208,605 | 12,095 | Form 4 |
| 2025-12-26 | Feld MichaelEVP, CRO & Pres. Life Sciences | Saleplan | 74 | 196.08 | $14,510 | 16,506 | Form 4 |
| 2025-12-17 | Garrison Michael DavidEVP & Pres Med.Essntl&BioPharm | Saleplan | 629 | 196.03 | $123,303 | 13,105 | Form 4 |
| 2025-12-01 | Feld MichaelEVP, CRO & Pres. Life Sciences | Saleplan | 75 | 193.36 | $14,502 | 16,580 | Form 4 |
| 2025-11-07 | Scott Bertram LDirector | Sale | 217 | 176.58 | $38,318 | 35,816 | Form 4 |
| 2025-10-27 | Feld MichaelEVP & President, Life Sciences | Saleplan | 57 | 186.01 | $10,603 | 8,245 | Form 4 |
| 2025-09-26 | Feld MichaelEVP & President, Life Sciences | Saleplan | 58 | 181.03 | $10,500 | 8,302 | Form 4 |
| 2025-09-10 | Fraser ClaireDirector | Sale | 917 | 187.50 | $171,938 | 22,226 | Form 4 |
| 2025-08-22 | Feld MichaelEVP & President, Life Sciences | Saleplan | 57 | 197.99 | $11,285 | 8,360 | Form 4 |
| 2025-08-11 | Hayes GregoryDirector | Buy | 5,250 | 191.57 | $1.01M | 6,046 | Form 4 |
| 2025-08-08 | Fraser ClaireDirector | Sale | 863 | 192.30 | $165,955 | 23,143 | Form 4 |
| 2025-07-18 | Garrison Michael DavidEVP & President, Medical | Saleplan | 1,184 | 180.29 | $213,463 | 4,888 | Form 4 |
| 2025-07-18 | Garrison Michael DavidEVP & President, Medical | Saleplan | 1 | 181.50 | $182 | 4,887 | Form 4 |
| 2025-06-02 | Shan DavidEVP and Chief ISC Officer | Saleplan | 1,166 | 171.19 | $199,608 | 4,575 | Form 4 |
| 2025-04-09 | Garrison Michael DavidEVP & President, Medical | Saleplan | 479 | 197.28 | $94,497 | 4,887 | Form 4 |
| 2025-03-18 | Byrd RichardEVP & President Interventional | Saleplan | 459 | 230.00 | $105,570 | 6,952 | Form 4 |
| 2025-03-12 | Byrd RichardEVP & President Interventional | Saleplan | 1,940 | 224.91 | $436,325 | 7,411 | Form 4 |
| 2025-02-12 | Scott Bertram LDirector | Sale | 700 | 227.99 | $159,593 | 36,033 | Form 4 |
| 2025-02-10 | Henderson Jeffrey WilliamDirector | Buy | 1,500 | 233.62 | $350,430 | 8,015 | Form 4 |
| 2025-01-21 | Neal Shana CarolEVP and Chief People Officer | Saleplan | 787 | 240.00 | $188,880 | 15,414 | Form 4 |
| 2025-01-21 | Shan DavidEVP and Chief ISC Officer | Saleplan | 500 | 240.00 | $120,000 | 5,741 | Form 4 |
| 2025-01-17 | Garrison Michael DavidEVP & President, Medical | Saleplan | 597 | 236.51 | $141,196 | 5,544 | Form 4 |
| 2025-01-07 | Neal Shana CarolEVP and Chief People Officer | Saleplan | 788 | 235.00 | $185,180 | 16,201 | Form 4 |
| 2024-12-19 | Garrison Michael DavidEVP & President, Medical | Saleplan | 2,838 | 223.33 | $633,811 | 6,141 | Form 4 |
4 more
| 2024-12-09 | Goette RolandEVP and President, EMEA | Saleplan | 638 | 219.03 | $139,741 | 14,217 | Form 4 |
| 2024-12-06 | Neal Shana CarolEVP and Chief People Officer | Saleplan | 1,000 | 220.49 | $220,490 | 16,989 | Form 4 |
| 2024-12-06 | Goette RolandEVP and President, EMEA | Saleplan | 4,483 | 221.01 | $990,788 | 24,345 | Form 4 |
| 2024-12-05 | Shan DavidEVP and Chief ISC Officer | Saleplan | 1,500 | 220.25 | $330,375 | 6,285 | Form 4 |
Grants, exercises and other transactions
Pay, tax and paperwork rather than a choice to trade at the market price. Two years.
68 × grant or award31 × shares withheld for tax7 × option exercise5 × returned to the company
Show them
| Date | Insider | What | Shares | Price | Holds after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-02 | Roque VitorEVP & Chief Financial Officer | Shares withheld for tax F | −190 | – | 8,041 | Form 4 |
| 2026-08-20 | Feld MichaelEVP, Chief Revenue Officer | Shares withheld for tax F | −1,049 | – | 19,885 | Form 4 |
| 2026-08-13 | Polen Thomas E JrDirector, Chairman, CEO and President | Option exercise M | +43,278 | 167.25 | 153,441 | Form 4 |
| 2026-08-13 | Polen Thomas E JrDirector, Chairman, CEO and President | Returned to the company D | −39,126 | 185.00 | 114,315 | Form 4 |
| 2026-07-02 | Muhsin BilalEVP & President Connected Care | Shares withheld for tax F | −1,935 | – | 41,359 | Form 4 |
| 2026-07-01 | Muhsin BilalEVP & President Connected Care | Grant or award A | +14,342 | – | 43,294 | Form 4 |
| 2026-06-01 | Polen Thomas E JrDirector, Chairman, CEO and President | Option exercise M | +20,209 | 126.16 | 125,680 | Form 4 |
| 2026-06-01 | Polen Thomas E JrDirector, Chairman, CEO and President | Returned to the company D | −17,445 | 146.15 | 108,235 | Form 4 |
| 2026-06-01 | Menziuso PeterEVP and President, BDI | Grant or award A | +14,258 | – | 14,258 | Form 4 |
| 2026-05-07 | Roque VitorEVP & Chief Financial Officer | Grant or award A | +1,721 | – | 8,231 | Form 4 |
| 2026-04-06 | Neal Shana CarolEVP and Chief People Officer | Shares withheld for tax F | −1,146 | – | 23,966 | Form 4 |
| 2026-03-16 | Minnix LaneshaEVP and General Counsel | Grant or award A | +7,492 | – | 7,492 | Form 4 |
| 2026-03-02 | Spikner Pamela L.SVP Controller & CAO | Grant or award A | +931 | – | 3,323 | Form 4 |
| 2026-03-02 | Roque VitorInterim CFO | Grant or award A | +931 | – | 6,510 | Form 4 |
| 2026-01-27 | Wright JacquelineDirector | Grant or award A | +1,098 | – | 1,279 | Form 4 |
| 2026-01-27 | Waldstreicher JoanneDirector | Grant or award A | +1,098 | – | 3,391 | Form 4 |
| 2026-01-27 | Scott Bertram LDirector | Grant or award A | +1,098 | – | 37,716 | Form 4 |
| 2026-01-27 | Ring Timothy MDirector | Grant or award A | +1,098 | – | 59,160 | Form 4 |
| 2026-01-27 | Jones Christopher Ian MontagueDirector | Grant or award A | +1,098 | – | 24,304 | Form 4 |
| 2026-01-27 | Huffines Robert LutherDirector | Grant or award A | +1,098 | – | 1,279 | Form 4 |
| 2026-01-27 | Brown William MDirector | Grant or award A | +1,098 | – | 4,663 | Form 4 |
| 2026-01-27 | Hayes GregoryDirector | Grant or award A | +1,098 | – | 7,159 | Form 4 |
| 2026-01-27 | Byington Carrie LDirector | Grant or award A | +1,098 | – | 5,018 | Form 4 |
| 2026-01-27 | Eckert R AndrewDirector | Grant or award A | +1,098 | – | 10,423 | Form 4 |
| 2026-01-27 | Henderson Jeffrey WilliamDirector | Grant or award A | +1,098 | – | 9,143 | Form 4 |
| 2026-01-21 | Spikner Pamela L.SVP Controller & CAO | Shares withheld for tax F | −84 | – | 1,832 | Form 4 |
| 2026-01-15 | Garrison Michael DavidEVP & Pres Med.Essntl&BioPharm | Option exercise M | +3,054 | 167.91 | 16,159 | Form 4 |
| 2026-01-15 | Garrison Michael DavidEVP & Pres Med.Essntl&BioPharm | Returned to the company D | −2,454 | 209.00 | 13,705 | Form 4 |
| 2026-01-03 | Shan DavidEVP and Chief ISC Officer | Shares withheld for tax F | −44 | – | 8,926 | Form 4 |
| 2025-12-01 | Huffines Robert LutherDirector | Grant or award A | +180 | – | 180 | Form 4 |
| 2025-12-01 | Wright JacquelineDirector | Grant or award A | +180 | – | 180 | Form 4 |
| 2025-11-26 | Spikner Pamela L.SVPController & Chief Acct Off | Grant or award A | +1,234 | – | 1,916 | Form 4 |
| 2025-11-26 | Polen Thomas E JrChairman, CEO and President | Grant or award A | +22,521 | – | 122,892 | Form 4 |
| 2025-11-26 | Polen Thomas E JrChairman, CEO and President | Shares withheld for tax F | −17,421 | – | 105,471 | Form 4 |
| 2025-11-26 | Muhsin BilalEVP & President Connected Care | Grant or award A | +9,530 | – | 21,751 | Form 4 |
| 2025-11-26 | Byrd RichardEVP & President Interventional | Grant or award A | +6,447 | – | 13,183 | Form 4 |
| 2025-11-26 | Byrd RichardEVP & President Interventional | Grant or award A | +2,385 | – | 15,568 | Form 4 |
| 2025-11-26 | Byrd RichardEVP & President Interventional | Shares withheld for tax F | −1,719 | – | 13,849 | Form 4 |
| 2025-11-26 | DelOrefice ChristopherEVP & Chief Financial Officer | Grant or award A | +6,006 | – | 27,227 | Form 4 |
| 2025-11-26 | DelOrefice ChristopherEVP & Chief Financial Officer | Shares withheld for tax F | −4,245 | – | 22,982 | Form 4 |
| 2025-11-26 | Feld MichaelEVP, CRO & Pres. Life Sciences | Grant or award A | +8,829 | – | 17,074 | Form 4 |
| 2025-11-26 | Feld MichaelEVP, CRO & Pres. Life Sciences | Shares withheld for tax F | −419 | – | 16,655 | Form 4 |
| 2025-11-26 | Garrison Michael DavidEVP & Pres Med.Essntl&BioPharm | Grant or award A | +7,568 | – | 12,455 | Form 4 |
| 2025-11-26 | Garrison Michael DavidEVP & Pres Med.Essntl&BioPharm | Grant or award A | +3,048 | – | 15,503 | Form 4 |
| 2025-11-26 | Garrison Michael DavidEVP & Pres Med.Essntl&BioPharm | Shares withheld for tax F | −1,769 | – | 13,734 | Form 4 |
| 2025-11-26 | Goette RolandEVP and President, EMEA | Grant or award A | +1,906 | – | 16,123 | Form 4 |
| 2025-11-26 | Goette RolandEVP and President, EMEA | Grant or award A | +1,237 | – | 17,360 | Form 4 |
| 2025-11-26 | Goette RolandEVP and President, EMEA | Shares withheld for tax F | −138 | – | 17,222 | Form 4 |
| 2025-11-26 | Neal Shana CarolEVP and Chief People Officer | Grant or award A | +6,727 | – | 20,255 | Form 4 |
| 2025-11-26 | Neal Shana CarolEVP and Chief People Officer | Grant or award A | +3,525 | – | 23,780 | Form 4 |
| 2025-11-26 | Neal Shana CarolEVP and Chief People Officer | Shares withheld for tax F | −2,454 | – | 21,326 | Form 4 |
| 2025-11-26 | Shan DavidEVP and Chief ISC Officer | Grant or award A | +3,504 | – | 8,079 | Form 4 |
| 2025-11-26 | Shan DavidEVP and Chief ISC Officer | Grant or award A | +1,025 | – | 9,104 | Form 4 |
| 2025-11-26 | Shan DavidEVP and Chief ISC Officer | Shares withheld for tax F | −134 | – | 8,970 | Form 4 |
| 2025-11-26 | Mocherla Pavan KumarEVP & President, Greater Asia | Grant or award A | +2,208 | – | 5,055 | Form 4 |
| 2025-11-26 | Mocherla Pavan KumarEVP & President, Greater Asia | Grant or award A | +708 | – | 5,763 | Form 4 |
| 2025-09-01 | Byrd RichardEVP & President Interventional | Shares withheld for tax F | −216 | – | 6,736 | Form 4 |
| 2025-09-01 | DelOrefice ChristopherEVP & Chief Financial Officer | Shares withheld for tax F | −278 | – | 21,221 | Form 4 |
| 2025-08-20 | Feld MichaelEVP & President, Life Sciences | Shares withheld for tax F | −773 | – | 8,417 | Form 4 |
| 2025-07-18 | Garrison Michael DavidEVP & President, Medical | Option exercise M | +6,360 | 147.68 | 11,247 | Form 4 |
| 2025-07-18 | Garrison Michael DavidEVP & President, Medical | Returned to the company D | −5,175 | 180.29 | 6,072 | Form 4 |
| 2025-07-02 | Muhsin BilalEVP & President Connected Care | Grant or award A | +12,221 | – | 12,221 | Form 4 |
| 2025-04-04 | Neal Shana CarolEVP and Chief People Officer | Shares withheld for tax F | −1,886 | – | 13,528 | Form 4 |
| 2025-03-26 | Hayes GregoryDirector | Grant or award A | +796 | – | 796 | Form 4 |
| 2025-03-01 | Garrison Michael DavidEVP & President Medical | Shares withheld for tax F | −178 | – | 5,366 | Form 4 |
| 2025-01-28 | Brown William MDirector | Grant or award A | +930 | – | 3,486 | Form 4 |
| 2025-01-28 | Waldstreicher JoanneDirector | Grant or award A | +930 | – | 2,270 | Form 4 |
| 2025-01-28 | Scott Bertram LDirector | Grant or award A | +930 | – | 36,733 | Form 4 |
| 2025-01-28 | Ring Timothy MDirector | Grant or award A | +930 | – | 57,915 | Form 4 |
| 2025-01-28 | Jones Christopher Ian MontagueDirector | Grant or award A | +930 | – | 22,701 | Form 4 |
| 2025-01-28 | Henderson Jeffrey WilliamDirector | Grant or award A | +930 | – | 6,515 | Form 4 |
| 2025-01-28 | Fraser ClaireDirector | Grant or award A | +930 | – | 24,006 | Form 4 |
| 2025-01-28 | Byington Carrie LDirector | Grant or award A | +930 | – | 3,834 | Form 4 |
| 2025-01-28 | Eckert R AndrewDirector | Grant or award A | +930 | – | 9,170 | Form 4 |
| 2025-01-28 | Burzik Catherine MDirector | Grant or award A | +930 | – | 14,264 | Form 4 |
| 2025-01-03 | Shan DavidEVP and Chief ISC Officer | Shares withheld for tax F | −44 | – | 6,241 | Form 4 |
| 2024-12-06 | Goette RolandEVP and President, EMEA | Option exercise M | +6,995 | 147.68 | 22,489 | Form 4 |
| 2024-12-06 | Goette RolandEVP and President, EMEA | Option exercise M | +6,339 | 167.91 | 28,828 | Form 4 |
| 2024-12-06 | Goette RolandEVP and President, EMEA | Returned to the company D | −9,490 | 221.01 | 14,855 | Form 4 |
| 2024-11-26 | Mocherla Pavan KumarEVP & President, Greater Asia | Shares withheld for tax F | −25 | – | 2,847 | Form 4/A |
| 2024-11-26 | Shan DavidEVP and Chief ISC Officer | Grant or award A | +1,110 | – | 6,803 | Form 4 |
| 2024-11-26 | Shan DavidEVP and Chief ISC Officer | Grant or award A | +1,106 | – | 7,909 | Form 4 |
| 2024-11-26 | Shan DavidEVP and Chief ISC Officer | Shares withheld for tax F | −124 | – | 7,785 | Form 4 |
| 2024-11-26 | Goette RolandEVP and President, EMEA | Grant or award A | +944 | – | 13,529 | Form 4 |
| 2024-11-26 | Goette RolandEVP and President, EMEA | Grant or award A | +2,161 | – | 15,690 | Form 4 |
| 2024-11-26 | Goette RolandEVP and President, EMEA | Shares withheld for tax F | −196 | – | 15,494 | Form 4 |
| 2024-11-26 | Garrison Michael DavidEVP & President, Medical | Grant or award A | +2,553 | – | 7,934 | Form 4 |
| 2024-11-26 | Garrison Michael DavidEVP & President, Medical | Grant or award A | +2,275 | – | 10,209 | Form 4 |
| 2024-11-26 | Garrison Michael DavidEVP & President, Medical | Shares withheld for tax F | −1,230 | – | 8,979 | Form 4 |
| 2024-11-26 | Feld MichaelEVP & President, Life Sciences | Grant or award A | +2,553 | – | 9,190 | Form 4 |
| 2024-11-26 | Ezell Antoine CEVP, President Americas & CMO | Grant or award A | +1,388 | – | 10,708 | Form 4 |
| 2024-11-26 | Ezell Antoine CEVP, President Americas & CMO | Grant or award A | +2,619 | – | 13,327 | Form 4 |
| 2024-11-26 | Ezell Antoine CEVP, President Americas & CMO | Shares withheld for tax F | −1,357 | – | 11,970 | Form 4 |
| 2024-11-26 | DelOrefice ChristopherEVP & Chief Financial Officer | Grant or award A | +4,884 | – | 17,676 | Form 4 |
| 2024-11-26 | DelOrefice ChristopherEVP & Chief Financial Officer | Grant or award A | +9,015 | – | 26,691 | Form 4 |
| 2024-11-26 | DelOrefice ChristopherEVP & Chief Financial Officer | Shares withheld for tax F | −5,192 | – | 21,499 | Form 4 |
| 2024-11-26 | Byrd RichardEVP & President Interventional | Grant or award A | +2,220 | – | 8,280 | Form 4 |
| 2024-11-26 | Byrd RichardEVP & President Interventional | Grant or award A | +2,275 | – | 10,555 | Form 4 |
| 2024-11-26 | Byrd RichardEVP & President Interventional | Shares withheld for tax F | −1,204 | – | 9,351 | Form 4 |
| 2024-11-26 | Polen Thomas E JrChairman, CEO and President | Grant or award A | +15,539 | – | 87,350 | Form 4 |
| 2024-11-26 | Polen Thomas E JrChairman, CEO and President | Grant or award A | +36,585 | – | 123,935 | Form 4 |
| 2024-11-26 | Polen Thomas E JrChairman, CEO and President | Shares withheld for tax F | −23,564 | – | 100,371 | Form 4 |
| 2024-11-26 | Quinn MichelleEVP and General Counsel | Grant or award A | +1,932 | – | 6,887 | Form 4 |
| 2024-11-26 | Quinn MichelleEVP and General Counsel | Grant or award A | +416 | – | 7,303 | Form 4 |
| 2024-11-26 | Quinn MichelleEVP and General Counsel | Shares withheld for tax F | −376 | – | 6,927 | Form 4 |
| 2024-11-26 | Neal Shana CarolEVP and Chief People Officer | Grant or award A | +2,109 | – | 18,498 | Form 4 |
| 2024-11-26 | Neal Shana CarolEVP and Chief People Officer | Shares withheld for tax F | −509 | – | 17,989 | Form 4 |
| 2024-11-26 | Mocherla Pavan KumarEVP & President Greater Asia | Grant or award A | +875 | – | 2,692 | Form 4 |
| 2024-11-26 | Mocherla Pavan KumarEVP & President Greater Asia | Grant or award A | +180 | – | 2,872 | Form 4 |
| 2024-11-21 | Neal Shana CarolEVP and Chief People Officer | Option exercise M | +111 | – | 17,021 | Form 4 |
| 2024-11-21 | Neal Shana CarolEVP and Chief People Officer | Shares withheld for tax F | −32 | – | 16,989 | Form 4 |
How to read it
- Buy, sale
- Code P and S on the form: shares bought or sold in the market, at the market price. The other codes are mostly pay (a grant, an option exercised) or tax (shares the company withheld), and say little about what the insider thinks of the price.
- Plan
- A sale or purchase under a Rule 10b5-1 plan, set up in advance and running on its own schedule. Since April 2023 the form has a box for it. Much executive selling is planned and says more about diversifying than about the company.
- Holds after
- The shares the insider still held after the trade, in the form the trade was in (directly, or indirectly through a trust or a fund).
- Value
- Shares times the price the form reports, which is often an average over several fills on the day.
Read from the SEC's own quarterly data sets of Forms 3, 4 and 5, and from each day's filings since the last one. A correcting amendment replaces the lines it restates. Every row links to its filing. None of this is advice: insiders sell for many reasons, and buy for fewer.